Retinal degeneration, including age-related macular degeneration and retinitis pigmentosa, is the most common cause of blindness in the UK and is largely untreatable. We hope to develop new biological approaches to treat these conditions.
We aim to better understand the clinical and biochemical consequences of retinal disease, and explain the genetic and environmental factors contributing to disease pathogenesis.
With a strong translational focus, our goal is to bring these to the clinic and benefit patients with both novel treatments and advancements in existing clinical imaging and diagnostics.
With access to world leading facilities, Manchester is a leading institute for retinal disease research with key focus areas in:
- studying the genetics of retinal eye diseases;
- immune regulation and its underlying contribution to age-related macular degeneration;
- ocular angiogenesis and associated diseases such as diabetic retinopathy and retinitis pigmentosa;
- clinical imaging, machine vision and the development of novel diagnostic devices;
- optogenetic approaches to restoring vision in retinal degeneration.